Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.69 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | GRK2 | P25098 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | PRKACA | P17612 | 2/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4853003 | 0.94 | GSK3B (0.65) | GSK3BCASP1ROCK2PRKCAGRK2 | |
| SCHEMBL4856466 | 0.93 | GSK3B (0.64) | GSK3BCASP1ROCK2PRKCAGRK2 | |
| SCHEMBL4848500 | 0.92 | GSK3B (0.62) | GSK3BCASP1ROCK2PRKCAGRK2 | |
| SCHEMBL4848952 | 0.92 | GSK3B (0.62) | GSK3BCASP1ROCK2PRKCAGRK2 | |
| SCHEMBL4856682 | 0.92 | GSK3B (0.69) | GSK3BCASP1ROCK2PRKCAGRK2 | |
| SCHEMBL4856280 | 0.92 | GSK3B (0.75) | GSK3BCASP1ROCK2PRKCAGRK2 | |
| SCHEMBL4848978 | 0.91 | GSK3B (0.61) | GSK3BCASP1ROCK2PRKCAGRK2 | |
| SCHEMBL4854602 | 0.90 | GSK3B (0.63) | GSK3BCASP1ROCK2PRKCAGRK2 | |
| SCHEMBL5226580 | 0.89 | GSK3B (0.72) | GSK3BCASP1ROCK2PRKCAGRK2 | |
| SCHEMBL4847289 | 0.89 | GSK3B (0.62) | GSK3BCASP1ROCK2PRKCAGRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| EP-1611121-B1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | disclosed |
| EP-1581505-B1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1581505-B1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1611121-A1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | Aventis Pharma S.A. (FR) | 2006-01-04 | — | — | EP | disclosed |
| EP-1581505-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004046117-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004046130-A1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | ADRA2C, ADRA1A, ADRA1B | GSK3B 3654/4885CASP1 2557/4885ROCK2 4094/4885 |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | C5, ADRA2C, ADRA1A | GSK3B 3708/4885CASP1 3371/4885ROCK2 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.